Colin Bristow
Stock Analyst at UBS
(1.00)
# 3,582
Out of 4,829 analysts
95
Total ratings
29.09%
Success rate
-16.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $14.50 | +17.24% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $275.04 | +15.98% | 8 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.05 | +280.95% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $2.90 | +141.38% | 2 | Feb 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $23.00 | +21.77% | 13 | Feb 5, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $4 → $2.2 | $0.43 | +407.50% | 5 | Jan 27, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $120 | $80.81 | +48.50% | 6 | Jan 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $47 → $71 | $45.86 | +54.82% | 3 | Dec 3, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $70 → $96 | $103.70 | -7.43% | 3 | Nov 21, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $562 → $586 | $439.14 | +33.44% | 13 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $124.00 | +62.90% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.49 | +973.83% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $574.53 | +91.29% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $54 | $7.20 | +650.00% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $36.81 | +353.68% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $755.40 | -44.40% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $4.02 | -50.25% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.75 | +2,289.80% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $191.16 | -23.62% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $48.11 | +55.89% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $1.57 | +1,556.05% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.10 | +76.47% | 1 | Aug 23, 2021 |
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $14.50
Upside: +17.24%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $275.04
Upside: +15.98%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.05
Upside: +280.95%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $2.90
Upside: +141.38%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $23.00
Upside: +21.77%
ALX Oncology Holdings
Jan 27, 2025
Maintains: Buy
Price Target: $4 → $2.2
Current: $0.43
Upside: +407.50%
Merck & Co.
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $80.81
Upside: +48.50%
PTC Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $47 → $71
Current: $45.86
Upside: +54.82%
Gilead Sciences
Nov 21, 2024
Maintains: Neutral
Price Target: $70 → $96
Current: $103.70
Upside: -7.43%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Buy
Price Target: $562 → $586
Current: $439.14
Upside: +33.44%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $124.00
Upside: +62.90%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.49
Upside: +973.83%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $574.53
Upside: +91.29%
Mar 1, 2024
Maintains: Buy
Price Target: $56 → $54
Current: $7.20
Upside: +650.00%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $36.81
Upside: +353.68%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $755.40
Upside: -44.40%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $4.02
Upside: -50.25%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $0.75
Upside: +2,289.80%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $191.16
Upside: -23.62%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $48.11
Upside: +55.89%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $1.57
Upside: +1,556.05%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.10
Upside: +76.47%